I am pretty comfortable with the current price being close to a...

I am pretty comfortable with the current price being close to a new floor. Most people who bought after the last FDA announcement (and sharp price decline) would still be in the money and so shaking a few out seems typical. This product and company is not going to be too bright and shiny. I would think of like a utility. Nuclear medicine services in the US are going to slowly shift across to this. Some will want to switch now, others will have to wait until existing contracts or supplies of alternatives are used up. But as the best existing product for an established test I am pretty confident they will sell a lot. Just might be a slow burn. Their revenue which peaked last year at 23mil is only going one way. Once they have market share in the US, they should be printing money. Just slower than some short term investors might like.